Isolinderalactone targets TNF-α/STAT3 inflammatory pathways to attenuate psoriasis-like dermatitis - PubMed
4 days ago
- #Psoriasis
- #Isolinderalactone
- #TNF-α/STAT3
- Isolinderalactone identified as a potent small-molecule drug targeting TNF-α/STAT3 inflammatory pathways.
- Topical application of Isolinderalactone significantly alleviated psoriasis-like dermatitis in a mouse model.
- RNA-seq analysis showed Isolinderalactone downregulated TNF-α, IL-17, and S100-related inflammatory factors in keratinocytes.
- Mechanistically, Isolinderalactone inhibited TNF-α/STAT3 pathways, exerting anti-inflammatory effects.
- Potential for topical Isolinderalactone therapy in mild-to-moderate psoriasis highlighted.